SILVER SPRING, Md., Aug. 1, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration (FDA) is warning U.S. consumers not to use the emergency birth control medicine labeled as Evital. These products may be counterfeit versions of the "morning after pill" and may not be safe or effective in preventing pregnancy.
Evital has not been approved by the FDA for use in the United States.
This potentially ineffective and suspect counterfeit emergency birth control may also be in distribution in some Hispanic communities in the United States.
The packaging label of the potentially ineffective and suspect counterfeit version says, "Evital Anticonceptivo de emergencia, 1.5 mg, 1 tablet", by "Fluter Domull" :
FDA is asking for help from consumers who have information about Evital. Please send an email to CDER_Ingredient_Adulteration@fda.hhs.gov to provide information or if you have more questions.
Any information received is confidential and will be used only to help in FDA's effort to remove the potentially unsafe and ineffective versions from the U.S. marketplace.
Health care professionals and consumers are asked to report adverse events related to the use of suspect counterfeit versions of Evital to the FDA's MedWatch Safety Information and Adverse Event Reporting Program either online, by regular mail, by fax, or by phone.
For more information about counterfeit medicine, click on link below:
The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.
Media Inquiries: Shelly Burgess 301-796-4651; firstname.lastname@example.org
Consumer Inquiries: 888-INFO-FDA
|SOURCE U.S. Food and Drug Administration|
Copyright©2010 PR Newswire.
All rights reserved